Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA

The treatment or prevention of bleeding in patients with hemophilia A relies on replacement therapy with different factor VIII (FVIII)-containing products or on the use of by-passing agents, i.e., activated prothrombin complex concentrates or recombinant activated factor VII. Emerging approaches inc...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica
Main Authors: Russick, Jules, Delignat, Sandrine, Milanov, Peter, Christophe, Olivier, Boros, Gábor, Denis, Cécile V., Lenting, Peter J., Kaveri, Srinivas V., Lacroix-Demazes, Sébastien
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109737/
https://ncbi.nlm.nih.gov/pubmed/31289204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.210583
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items